STOCK TITAN

Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Freenome (NASDAQ: FRNM) management will participate in the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026.

The fireside chat is scheduled for 4:30pm to 4:55pm Eastern Time. A live and archived webcast will be available in the Events section of Freenome’s investor relations website.

Loading...
Loading translation...

Key Terms

cell-free dna
1 terms
cell-free dna technical
"analyzes circulating cell-free DNA methylation patterns"
Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests, today announced company management will participate in the Piper Sandler 38th Annual Healthcare Conference.

Management will participate in a fireside chat from 4:30pm to 4:55pm Eastern Time on Tuesday, Dec. 1, 2026.

A live and archived webcast of the events will be available on the “Events” section of the Freenome investor relations website at https://investors.freenome.com/news-events/events.

About Freenome

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary AI-driven multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of FDA-approved SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional single- and multi-cancer indications is designed to increase cancer screening participation among millions of at-risk individuals.

Freenome Contacts:

Investor Relations
Gilmartin Group LLC
investor-relations@freenome.com

Media Contact
Ryan Flinn
The Grace Group
ryan@gracegroup.us
media@gracegroup.us


Keep reading